|1.||Thomas, Candice M: 1 article (01/2013)|
|2.||Baker, Kenneth M: 1 article (01/2013)|
|3.||Seqqat, Rachid: 1 article (01/2013)|
|4.||Yong, Qian Chen: 1 article (01/2013)|
|5.||Chandel, Niketa: 1 article (01/2013)|
|6.||Kumar, Rajesh: 1 article (01/2013)|
|7.||Kuwahara, Yasuhito: 1 article (06/2003)|
|8.||Kitagawa, Hitoshi: 1 article (06/2003)|
|9.||Kitoh, Katsuya: 1 article (06/2003)|
|10.||Kondo, Masahiro: 1 article (06/2003)|
10/01/1998 - "Protective effects of valsartan and benazeprilat in salt-loaded stroke-prone spontaneously hypertensive rats."
10/01/1998 - "These experiments examined the effectiveness of chronic blockade of the renin angiotensin system with either valsartan or benazeprilat on survival, blood pressure and end-organ damage in salt-loaded stroke-prone SHR. "
10/01/1998 - "Valsartan or benazeprilat given continuously by subcutaneous osmotic minipump beginning at 10.5 weeks of age lowered blood pressure, as determined by radiotelemetry, prevented proteinuria, prolonged survival and decreased the severity of histopathological changes in the heart and kidney. "
06/01/2003 - "In 7 dogs with ascitic pulmonary heartworm disease, plasma benazeprilat concentrations tended to be higher than in 7 control dogs both on the 1st and 7th administration days. "
06/01/2003 - "In dogs with ascitic heartworm disease, benazepril was readily transformed to benazeprilat by the liver, and was effective for suppression of plasma ACE activity."
06/01/2003 - "An angiotensin converting enzyme inhibitor, benazepril can be transformed to an active metabolite, benazeprilat, by the liver of dogs with ascitic pulmonary heartworm disease."
06/01/2003 - "To examine whether an angiotensin converting enzyme (ACE) inhibitor, benazepril, can be transformed to the active metabolite, benazeprilat, by severely injured liver of dogs with ascitic heartworm disease, benazepril hydrochloride was administered orally to dogs once daily for 7 consecutive days at a dose rate of 0.29 mg/kg to 0.63 mg/kg of body weight, and plasma benazepril and benazeprilat concentrations were determined on the 1st and 7th administration days. "
10/01/2001 - "In a second study, myocardial microdialysis was used to measure porcine interstitial BK levels in both normal (n = 14) and pacing-induced congestive heart failure (CHF) (240 beats/min, 3 weeks, n = 16) under the following conditions: baseline, following ACEI (benezaprilat, 0.0625 mg/kg) or AT(1) block (valsartan, 0.1 mg/kg), and a combined treatment (benezaprilat, 0.0625 mg/kg; valsartan, 0.1 mg/kg). "
01/01/1988 - "These data indicate that the nonsulfhydryl ACE inhibitors CGS 14831 and CGS 16617 have a significant cardioprotective effect in rats surviving 48 h, and suggest a potential therapeutic usefulness of these agents for the treatment of ischemia-induced heart failure."
08/01/1997 - "ACE inhibitors can also be classified according to the excretion route of their active moiety, into 2 different excretion route types:(1) excreated mainly through the kidney such as captopril, enalaprilat, lisinopril, benazeprilat, imdaprilat, trandraprilat, etc.; (2) excreated both in the bile and urine such as fosinoprilat, temocaprilat, zofenoprilat etc. ACE inhibitors have clinically beneficial effects not only for patients with either hypertension or congestive heart failure, but also can be used to prevent the progression of renal dysfunction induced by hypertension and diabetes mellitus."
|5.||Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
01/01/1988 - "Effects of two nonsulfhydryl angiotensin-converting enzyme inhibitors, CGS 14831 and CGS 16617, on myocardial damage and left-ventricular hypertrophy following coronary artery occlusion in the rat."
01/01/1988 - "The present study was designed to examine the effects of two new angiotensin-converting enzyme (ACE) inhibitors, CGS 14831 and CGS 16617 (3 mg/kg i. v. 1 min prior to occlusion and 4 and 24 h after occlusion), on myocardial ischemic (MI) damage and left-ventricular hypertrophy in rats. "
|3.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|4.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|1.||Surgical Instruments (Clip)